InterAx and Alveus: Strategic research and licensing agreement

This partnership forms a joint research effort on a target and modality of established but untapped therapeutic interest by combining InterAx’s Deep Signal discovery platform – designed to optimize candidates toward superior signaling profiles – with Alveus’s deep R&D expertise and leadership in obesity, diabetes, and cardiometabolic disease. While financial terms remain undisclosed, the agreement includes an upfront payment and eligibility for future development, regulatory, and commercial milestones.

“We are thrilled to join forces with Alveus to advance a highly differentiated therapeutic candidate designed to overcome the limitations of today’s obesity medications,” said Andrew Roberts, CEO of InterAx. “Our Deep Signal platform is specifically designed to navigate the complexity of GPCR signaling, and Alveus’s deep metabolic expertise makes them the ideal partner to bring this therapeutic candidate to patients.”

“InterAx’s unique platform integrates drug chemistry, protein structure, cellular signaling and therapeutic efficacy – the essential expertise for effectively and efficiently designing highly differentiated candidates. We are excited to apply this unique approach to our joint program efforts,” said Jacob Jeppesen, Chief Scientific Officer and Head of R&D at Alveus.